SC
SABS icon

Stempoint Capital’s SAB Biotherapeutics SABS Stock Holding History

Stempoint Capital’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Buy
375,000
+228,442
+156% +$911K 0.28% 59
2025
Q4 		$548K Buy
+146,558
New +$482K 0.09% 71

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Stempoint Capital's SABS Position: Q1 2026 in Review

Stempoint Capital increased its SAB Biotherapeutics (SABS) stake by 156% in Q1 2026, buying an estimated $911K and bringing the position to 375,000 shares worth $1.44M. The position accounts for 0.28% of the portfolio, ranked #59.

Stempoint Capital first reported a position in SABS in Q4 2025 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Stempoint Capital held 375,000 shares of SAB Biotherapeutics worth $1.44M as of Q1 2026.
  • Stempoint Capital bought 228,442 SAB Biotherapeutics shares in Q1 2026, an estimated $911K.
  • SAB Biotherapeutics made up 0.28% of Stempoint Capital's portfolio in Q1 2026, its #59 holding.
  • Stempoint Capital first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.